SIGNIFICANCE OF THE SERUM MARKER OF CARDIAC FIBROSIS AND INFLAMMATION IN THE PROGNOSIS OF PERMANENT ATRIAL FIBRILLATION

Shokirova M. Sh., Usmanova D. N., Tulkinzhanova G. R.

Authors

Shokirova M. Sh., Usmanova D. N., Tulkinzhanova G. R. Andijan State Medical Institute

Keywords:

Atrial fibrillation, terminal procollagen type I propeptide, tumor necrosis factory-α, interleukin-6.

Abstract

Indicators of cardiac fibrosis of mediators of systemic inflammation in patients withatrial fibrillation(AF) depending on the form of arrhythmia were studied. It was found that in AF, the levels of serum markers of fibrosis and inflammation increase: The C-terminal propeptide of procollagen type I (PICP), interleukin-6. There is a dependence of fibrosis indicators on the form of AF. The level of PICP increases in chronic permanent форме AF. In patients with recurrent AF, the IL-6 index has higher values compared to those in practically healthy people and increases even more in permanent AF. The level of tumor necrosis factor α is slightly increased in permanent AF.

References

Camm A., Kirchhof P., Lip G. et al. ESC Guidelines for the Management of Atrial fibrillation (2010 Version). Eur. Heart J. 2010; 6: 1—61.

Savchenko A. P., Zhirov I. V., Rudenko B. A. et al. Endovascular application устройства of the WATCHMAN device for the prevention of thromboembolic complications in a patient with atrial fibrillation. Cardiology. 2012; 8: 93—6.

Aldhoon B., Melenovsky V., Peichl P., Kautzner J. New insights into mechanisms of atrial fibrillation. Physiol. Res. 2010; 59 (1): 1—12.

Nguyen B., Fishbein M., Chen L. et al. Histopathological substrate for chronic atrial fibrillation in humans. Heart Rhythm. 2009; 6 (4): 454—60.

Spach M., Boineau J. Microfibrosis produces electrical load variations due to loss of side-to-side cell connections: a major mechanism of structural heart disease arrhythmias. Pacing Clin. Electrophysiol. 1997; 20: 397—413.

Wolk R., Cobbe S., Hicks M., Kane K. Functional, structural, and dynamic basis of electrical heterogeneity in healthy and diseased cardiac muscle: implications for arrhythmogenesis and anti-arrhythmic drug therapy. Pharmacol. Ther. 1999; 84 (2): 207—31.

Gluba A., Bielecka A., Mikhailidis D., et al. An update on biomarkers of heart failure in hypertensive patients. J. Hypertens. 2012; 30 (9): 1681—9.

Lоpez B., Gonzаlez A., Querejeta R. et al. The use of collagen- derived serum peptides for the clinical assessment of hypertensive heart disease. J. Hypertens. 2005; 23 (8): 1445—51.

Macias B., Fatela-Cantillo D., Jiménez L. et al. Left ventricular mass, diastolic function and collagen metabolism biomarkers in essential hypertension. Med. Clin. (Barc). 2012; 138 (4): 139—44.

Frustaci A., Chimenti C., Bellocci F. et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997; 96 (4): 1180—4.

Grigoryan S. V., Azarapetyan L. G., AdamyanK. G. Comparative assessment of markers of inflammation andfibrosisin patients withvarious clinical forms of atrial fibrillation. // Cardiovascular therapy andprevention. 2018;17(6):26–31. http://dx.doi.org/10.15829/1728-8800-2018-6-26-31